Titre:
  • TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
Auteur:Bonnefoi, Herve; Piccart-Gebhart, Martine; Bogaerts, Jan; Mauriac, Louis; Fumoleau, Pierre; Brain, Etienne; Petit, Thierry; Rouanet, Philippe; Jassem, Jacek; Blot, Emmanuel; Zaman, Khalil; Cufer, Tanja; Lortholary, Alain; Lidbrink, Elisabet; André, Sylvie; Litière, Saskia; Dal Lago, Lissandra; Becette, Véronique; Cameron, David A; Bergh, Jonas; Iggo, Richard; EORTC 10994/BIG 1-00 Study Investigators,
Informations sur la publication:Lancet oncology, 12, 6, page (527-539)
Statut de publication:Publié, 2011-06
Sujet CREF:Cancérologie
MeSH keywords:Adult
Aged
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- chemistry -- drug therapy -- mortality
Female
Humans
Middle Aged
Mutation
Neoadjuvant Therapy
Receptor, erbB-2 -- analysis
Receptors, Estrogen -- analysis
Taxoids -- administration & dosage -- therapeutic use
Tumor Suppressor Protein p53 -- genetics -- physiology
Note générale:Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1470-2045
info:doi/10.1016/S1470-2045(11)70094-8
info:pii/S1470-2045(11)70094-8
info:scp/79957527931
info:pmid/21570352